X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (114) 114
oncology (108) 108
index medicus (101) 101
middle aged (83) 83
male (78) 78
female (75) 75
aged (72) 72
chemotherapy (72) 72
cancer (69) 69
gastric cancer (54) 54
antineoplastic combined chemotherapy protocols - therapeutic use (53) 53
adult (52) 52
stomach cancer (52) 52
stomach neoplasms - drug therapy (42) 42
medicine & public health (38) 38
stomach neoplasms - pathology (38) 38
care and treatment (35) 35
treatment outcome (32) 32
cancer research (31) 31
metastasis (30) 30
analysis (28) 28
research (28) 28
aged, 80 and over (27) 27
retrospective studies (27) 27
surgical oncology (27) 27
disease-free survival (26) 26
drug combinations (26) 26
trial (26) 26
fluorouracil (25) 25
prognosis (24) 24
tumors (24) 24
antineoplastic agents - therapeutic use (23) 23
colorectal neoplasms - drug therapy (23) 23
gastroenterology (23) 23
clinical trials (22) 22
colorectal cancer (22) 22
patients (22) 22
survival (22) 22
survival rate (22) 22
cisplatin (21) 21
gastroenterology & hepatology (21) 21
cetuximab (19) 19
drug administration schedule (19) 19
liver neoplasms - secondary (19) 19
tegafur - administration & dosage (19) 19
abdominal surgery (18) 18
antimitotic agents (18) 18
antineoplastic agents (18) 18
camptothecin - analogs & derivatives (18) 18
oxonic acid - administration & dosage (18) 18
adenocarcinoma (17) 17
antibodies, monoclonal - therapeutic use (17) 17
cancer patients (17) 17
cancer therapies (17) 17
neoplasm staging (17) 17
1st-line therapy (16) 16
cisplatin - administration & dosage (16) 16
double-blind (16) 16
fluorouracil - administration & dosage (16) 16
oncology, experimental (16) 16
oxaliplatin (16) 16
antineoplastic combined chemotherapy protocols - adverse effects (15) 15
bevacizumab (15) 15
japan (15) 15
surgery (15) 15
camptothecin - administration & dosage (14) 14
colorectal neoplasms - pathology (14) 14
lymphatic metastasis (14) 14
paclitaxel (14) 14
stomach neoplasms - mortality (14) 14
antibodies, monoclonal, humanized (13) 13
combination (13) 13
drug therapy (13) 13
kaplan-meier estimate (13) 13
liver neoplasms - drug therapy (13) 13
metastases (13) 13
neoplasm metastasis (13) 13
organoplatinum compounds - administration & dosage (13) 13
hematology, oncology and palliative medicine (12) 12
irinotecan (12) 12
leucovorin (12) 12
s-1 (12) 12
therapy (12) 12
adenocarcinoma - drug therapy (11) 11
antibodies, monoclonal - administration & dosage (11) 11
capecitabine (11) 11
mutation (11) 11
neoplasms. tumors. oncology. including cancer and carcinogens (11) 11
phase-iii (11) 11
quality of life (11) 11
safety (11) 11
studies (11) 11
1st-line treatment (10) 10
5-fluorouracil (10) 10
antineoplastic agents - adverse effects (10) 10
colorectal neoplasms - genetics (10) 10
expression (10) 10
follow-up studies (10) 10
medical research (10) 10
medicine, experimental (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 10/2018, Volume 29, Issue suppl_7
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2017, Volume 28, Issue suppl_9
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2016, Volume 27, Issue suppl_7
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2014, Volume 25, Issue suppl_5, pp. v17 - v17
Journal Article
Annals of the New York Academy of Sciences, ISSN 0077-8923, 04/2018, Volume 1417, Issue 1, pp. 104 - 115
Journal Article
Annals of the New York Academy of Sciences, ISSN 0077-8923, 04/2018, Volume 1417, Issue 1, pp. 104 - 115
Cancer immunotherapy involving blockade of immune checkpoint molecules, such as CTLA‐4 and PD‐1, has shown remarkable clinical success across several types of... 
regulatory T cells | OX40 | CTLA‐4 | PD‐1 | PD‐L1 | PD-l1 | CTLA-4 | Regulatory T cells | PD-1 | PD-1 BLOCKADE | MULTIDISCIPLINARY SCIENCES | INDUCTION | SUPPRESSION | TUMOR-IMMUNITY | GROWTH-FACTOR-BETA | MELANOMA | PD-L1 | IMMUNE TOLERANCE | NIVOLUMAB | CARCINOMA | SELF-TOLERANCE | Glucocorticoid-Induced TNFR-Related Protein - antagonists & inhibitors | Immunotherapy - methods | T-Lymphocytes, Regulatory - classification | Interleukin-2 Receptor alpha Subunit - antagonists & inhibitors | Receptors, CCR4 - immunology | HSP70 Heat-Shock Proteins - antagonists & inhibitors | Humans | Antibodies, Monoclonal - therapeutic use | Vascular Endothelial Growth Factor A - immunology | Vascular Endothelial Growth Factor A - antagonists & inhibitors | CTLA-4 Antigen - immunology | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Receptors, OX40 - immunology | Receptors, CCR4 - antagonists & inhibitors | T-Lymphocytes, Regulatory - immunology | Models, Immunological | Neoplasms - therapy | Neoplasms - immunology | Transforming Growth Factor beta - antagonists & inhibitors | Glucocorticoid-Induced TNFR-Related Protein - immunology | CTLA-4 Antigen - antagonists & inhibitors | Indoleamine-Pyrrole 2,3,-Dioxygenase - antagonists & inhibitors | Interleukin-2 Receptor alpha Subunit - immunology | Receptors, OX40 - antagonists & inhibitors | Development and progression | Care and treatment | Drug therapy | T cells | Immunotherapy | Cancer | Immunoregulation | Medical treatment | Medical services | Homeostasis | Immunosurveillance | Lymphocytes T | Immunity | Patients | Molecular chains | Anticancer properties | CD4 antigen | Inhibitors | Immune checkpoint | Lymphocytes | Foxp3 protein | Antitumor activity | Tumors
Journal Article
The Lancet, ISSN 0140-6736, 03/2019, Volume 393, Issue 10176, pp. 1099 - 1099
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 06/2019, Volume 16, Issue 6, pp. 356 - 371
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 640 - 653
Summary Background Although trastuzumab plus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric cancer, there is... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | SUPPORTIVE CARE | WEEKLY PACLITAXEL | ONCOLOGY | 2ND-LINE CHEMOTHERAPY | IRINOTECAN | LEVEL | PLUS PACLITAXEL | HER2 | CANCER | DOCETAXEL | Follow-Up Studies | Febrile Neutropenia - chemically induced | Humans | Middle Aged | Male | Stomach Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Taxoids - therapeutic use | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Aged, 80 and over | Adult | Female | Stomach Neoplasms - chemistry | Adenocarcinoma - chemistry | Taxoids - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Bridged-Ring Compounds - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Anemia - chemically induced | Survival Rate | Thrombocytopenia - chemically induced | Stomach Neoplasms - drug therapy | Maytansine - therapeutic use | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Esophagogastric Junction | Gastrointestinal Hemorrhage - chemically induced | Retreatment | Intention to Treat Analysis | Bridged-Ring Compounds - adverse effects | Aged | Receptor, ErbB-2 - analysis | Trastuzumab | Adenocarcinoma | Medical research | Chemotherapy | Clinical trials | Medicine, Experimental | Metastasis | Esophageal cancer | Cancer | Analysis
Journal Article
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 3/2019, Volume 26, Issue 3, pp. 919 - 920
Journal Article
Gan to kagaku ryoho. Cancer & chemotherapy, ISSN 0385-0684, 09/2017, Volume 44, Issue 9, p. 717
It has been reported that favorable influences of cytotoxic agents to anti-tumor immune response included immunogenic cell death and suppression of regulatory... 
Cytotoxins - therapeutic use | Neoplasms - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Humans | Immunotherapy | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Molecular Targeted Therapy | Neoplasms - pathology | Neoplasms - drug therapy
Journal Article
Gastric Cancer, ISSN 1436-3291, 1/2016, Volume 19, Issue 1, pp. 183 - 191
This study was conducted to investigate whether human epidermal growth factor receptor 2 (HER2) status, epidermal growth factor receptor (EGFR) status, and... 
Gastroesophageal junction cancer | Medicine & Public Health | Human epidermal growth factor receptor 2 | Gastroenterology | Abdominal Surgery | Oncology | Cancer Research | c-MET | Surgical Oncology | Gastric cancer | Epidermal growth factor receptor | 1ST-LINE TREATMENT | CLINICAL-FEATURES | LABEL PHASE-3 TRIAL | GROWTH-FACTOR RECEPTOR | OVEREXPRESSION | ONCOLOGY | DOUBLE-BLIND | CARCINOMAS | ESOPHAGOGASTRIC JUNCTION | GASTROENTEROLOGY & HEPATOLOGY | GENE COPY NUMBER | EXPRESSION | Proto-Oncogene Proteins c-met - metabolism | Receptor, Epidermal Growth Factor - genetics | Adenocarcinoma - pathology | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Receptor, ErbB-2 - metabolism | Male | Stomach Neoplasms - pathology | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Receptor, Epidermal Growth Factor - metabolism | Biomarkers, Tumor - metabolism | Esophageal Neoplasms - mortality | Female | Adenocarcinoma - genetics | Retrospective Studies | Stomach Neoplasms - genetics | Esophagogastric Junction - pathology | Oxonic Acid - administration & dosage | Stomach Neoplasms - drug therapy | Proto-Oncogene Proteins c-met - genetics | Esophageal Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Biomarkers, Tumor - genetics | Stomach Neoplasms - mortality | Drug Combinations | Adenocarcinoma - mortality | Immunohistochemistry | Cancer patients | Care and treatment | Chemotherapy | Patient outcomes | Analysis | Cytogenetics | Stomach cancer | Formaldehyde | Cancer
Journal Article
Cancer Science, ISSN 1347-9032, 12/2016, Volume 107, Issue 12, pp. 1843 - 1850
This randomized phase II trial compared panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) with bevacizumab plus FOLFIRI as second‐line... 
colorectal cancer | RAS mutation | panitumumab | liquid biopsy | Bevacizumab | 1ST-LINE TREATMENT | LEUCOVORIN | MULTICENTER | DETERMINANTS | PHASE-III | ACQUIRED-RESISTANCE | FLUOROURACIL | TRIAL | CETUXIMAB | ONCOLOGY | 2ND-LINE TREATMENT | ras Proteins - genetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Biomarkers, Tumor | Fluorouracil - therapeutic use | Neoplasm Metastasis | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Leucovorin - therapeutic use | Proto-Oncogene Proteins B-raf | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Bevacizumab - administration & dosage | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Treatment Outcome | Retreatment | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Alleles | Aged | Mutation | Antimitotic agents | Chemotherapy | Endothelial growth factors | Analysis | Oncology, Experimental | Colorectal cancer | Clinical trials | Metastasis | Research | Antineoplastic agents | Blood proteins | Cancer | Immunoassay | Colorectal carcinoma | Values | Oncology | Serum proteins | Cancer therapies | K-Ras protein | Metastases | Proteins | Oxaliplatin | Epidermal growth factor | Vascular endothelial growth factor | Deoxyribonucleic acid--DNA | Immunoglobulins | Survival | Patients | Studies | Irinotecan | Biomarkers | Ligands | Original
Journal Article
Journal Article
International Journal of Clinical Oncology, ISSN 1341-9625, 7/2019, Volume 24, Issue 7, pp. 779 - 788
Journal Article